This latest MDx report details the market landscape of the MDx industry from 2007 to 2015LOS ANGELES, CA (DeciBio – February 9th, 2012) - Today, DeciBio released the 4th edition of its molecular diagnostics (MDx) report. The report details the market size, segmentation, growth and trends of the MDx industry from 2007 to 2015. The 4th edition contains the following updates:

• 2011 actual financials incorporated: Company revenue / growth forecasts have been updated to include actual reported 2011 financials for major market players (e.g., Abbott , Cepheid , Genomic Health , Myriad Genetics , Qiagen , Roche , Siemens ) and minor market players (e.g., GenMark , Hologic , Life Technologies, Luminex , Monogram Biosciences (LabCorp))

• Market growth by segment extended to 2015: For each of the 25+ segments assessed in this report, we provide growth estimates through 2015 (extended from 2013 in the 3rdedition of this report). The market is segmented by:

• 4 therapeutic areas (infectious diseases, oncology, HPV, others)
• 8 technologies (PCR, qPCR, TMA, hybrid capture, CE Sequencing, NGS, FISH, other)
• 2 ranges of analytes tested (low and high plex level)
• 5 test rationales (predisposition, screening, diagnosis, therapy selection, monitoring)
• 4 test locations (reference labs, academic hospitals, blood banks, other)
• 4 geographies (U.S., Europe, Japan, rest of the world)

• This 4th edition cites a number of emerging companies that innovate in specific MDx niches of the market (e.g., point-of-care, emerging technologies, IVDMIA)
• The new edition contains 60 additional pages, including additional color and granularity to help understand key products in each category
• This report includes feedback from 12 additional experts

Authors: Stephane Budel, Partner at DeciBio, LLCConnect with Stephane Budel on Google+https://plus.google.com/+StephaneBudel